Abstract: The identification and quantitation of cell-surface proteins expressed by leukocytes currently use the wide availability of monoclonal antibodies (mAb) in immunohistochemical and flow cytometric assays. Presently, ϳ400 such proteins have been characterized; however, analysis of the completed human genome sequence indicates that it may contain several thousand as-yet unidentified molecules, which may be expressed on the leukocyte cell surface. Recent advances in protein isolation and analysis using mass spectrometry illustrate that it is now feasible to identify the protein composition of a complex sample such as a plasma membrane extract. Such an approach may be useful for the identification of the cell-surface proteins that have not been identified using mAb techniques. Here, we detail the results of an in silico evaluation of the peptides isolated using two methods used to label plasma membrane proteins to determine whether these methods are suitable for the identification of known leukocyte cell-surface proteins by mass spectrometry. The labeling of cell-surface proteins before isolation and characterization is a valuable means of differentiating between plasma membrane and internal membrane proteins The results indicate that although the majority of cell-surface proteins can be identified using either of the approaches, others known to be important diagnostically and/or therapeutically would not be identified using either approach. The implication of this for the use of these techniques in the discovery of new leukocyte cell-surface proteins is discussed. J. Leukoc. Biol. 77: 190 -198; 2005. 
INTRODUCTION
Plasma membrane proteins expressed by leukocytes are involved in a range of critical functions, such as antigen-specific activation of cells, leukocyte-to-leukocyte and leukocyte-toendothelium adhesion, the response to cytokines and chemokines, and the identification and removal of pathogens. Between 1982 and 2000, seven human leukocyte differentiation antigen (HLDA) workshops have collated information on 247 cell-surface "CD molecules," expressed by human leukocytes and malignant cells derived from them, using monoclonal antibodies (mAb) as a primary means of identification [1] . This represents a total of 320 individual molecules and 261 protein molecules. In various combinations, almost all of the CD molecules can be used to define stages of cellular development or activation of the cells of the immune system. This knowledge is used in the research, diagnosis, and therapy of conditions that have an immunological involvement, such as leukemia and lymphoma [2] , human immunodeficiency virus [3] , and hematopoietic progenitor cell transplantation [4] .
The CD molecules represent only a small fraction of the total of plasma membrane proteins expressed by leukocytes. The preparations for the eighth HLDA workshop identified ϳ200 "potential CD molecules" (see http://www.hlda8.org/PotentialCDs.htm), which have been characterized using mAb and/or gene analysis techniques [1, 5] . Using recent experimental data, it is possible to derive an estimate of the number of cell-surface proteins expressed by leukocytes [5] . The human genome is predicted to encode 23,758 genes and can express 34,091 transcripts (Ensembl build v21.34d.1, May 10, 2004 ; http://www.ensembl.org/Homo_sapiens/whatsnew/index.html). Expressed sequence tag data indicate that individual leukocyte populations express between 6000 and 17,000 genes, depending on their activation state [6] . Various studies predict that between 15% and 20% of the protein sequences in the human genome have one or more transmembrane helices [7] . These results imply that leukocytes may express several thousand membrane proteins, most of which remain to be identified and characterized. This estimate does not include some types of cell-surface proteins, such as glycosylphosphatidylinositol-anchored proteins, which may not have transmembrane domains. The failure of current approaches to generate these reagents may be a result of a variety of reasons, such as low copy number and lack of immunogenicity as a result of high sequence identity with the equivalent protein in the species used to make antibodies. The identification of these molecules and the generation of suitable high-affinity binding reagents would facilitate the evaluation of these proteins as diagnostic or therapeutic targets.
Mass spectrometry (MS)-based sequencing of peptide fragments is increasingly being used to define the protein composition of a complex mixture and has been used to characterize protein expression by different populations of leukocytes. Several publications describing the partial analysis of leukocyte whole-cell protein extracts using 1-dimensional or 2-dimensional electrophoresis followed by MS analysis [8 -10] suggest that this approach is relatively inefficient in identifying plasma membrane proteins, which have been identified using electrophoresis followed by MS in the analysis of detergent-resistant lipid raft domains of the membrane. However, these tend to be cytoskeletal proteins (e.g., flotillin, ␣-actinin, and moesin) and signaling molecules rather than integral membrane proteins [10 -13] . Although the analysis of membrane lipid rafts does focus the analysis to the plasma membrane, only a fraction of the plasma membrane proteins is found in lipid rafts and the raft composition changes depending on the activation state of the cells, and relatively few of the known CD molecules have been identified in such preparations.
Two factors that contribute to the difficulty in analyzing membrane proteins by approaches based on electrophoresis followed by MS are the highly hydrophobic nature of many integral membrane proteins and the presence of post-translational modifications such as N-linked glycosylation. The partial fractionation of complex mixtures of proteins using specific labeling of proteins followed by affinity chromatography can be used in the MS-based identification of leukocyte plasma membrane proteins, which have not been identified using mAbbased approaches. The simplest labeling procedure is the biotinylation of cell-surface proteins using a water-soluble reagent such as sulfo-NHS-LC-biotin [14] . Although this approach proved useful to isolate CD molecules, over 40% of the proteins identified by MS-based sequencing were nonplasma membrane proteins. Cell-surface proteins can be labeled in preference to intracellular proteins by incubating intact cells using lipid-insoluble, maleimide-based, thio-reactive reagents [15, 16] or through N-linked carbohydrates using hydrazidebased reagents [17] . Alternatively, cell-surface glycoproteins can be purified using lectin affinity chromatography and then tagged with the required isotope during deglycosylation [18] . An analysis of protein expression using (thiol-based) isotopecoded affinity tag reagents identified many CD molecules in a microsomal extract of HL-60 cells [16] . This analysis also identified a number of "hypothetical" proteins (proteins predicted from open reading frames of the human genome sequence), some of which may be cell-surface molecules.
Although these methods can lead to the discovery of previously unidentified plasma membrane proteins, it is not clear what proportion of proteins may be missed by any of these approaches. To gain some insight into the value of methods based on protein labeling through cysteines or glycosylation sites, we analyzed all 261 protein CD molecules to determine the likelihood that these known cell-surface proteins would be identified using these methods. This provides an indication of the proportion of typical membrane proteins that may be amenable to identification by MS following isolation using the approaches described. We find that a significant number of known CD molecules may not be identified by these methods, including several molecules that are currently important diagnostically and/or therapeutically. This suggests that a single approach will not be sufficient to generate a complete catalog of the proteins expressed on the surface of a cell and also indicates that additional alternatives to the isolation of plasma membrane proteins will need to be developed.
MATERIALS AND METHODS

Sequence identifiers for the CD proteins
The primary source of sequence identifiers for the CD proteins was the SwissProt identifier listed in the "CD nomenclature for surface proteins of human leukocytes" page of the Human Proteomics Initiative on the ExPASy website (http://www.expasy.org/cgi-bin/lists?cdlist.txt). The remaining identifiers were located by searching the ExPASy site with the gene names or protein accession numbers as listed in the Locus Link database (http://www.ncbi.nlm.nih.gov/LocusLink/). If this could not identify the protein, the protein sequence was identified from the National Center for Biotechnology Information (NCBI) database, and this was used in a BLAST search of the SwissProt and TrEMBL databases (http://www.expasy.org/tools/blast/). Where SwissProt identifiers could not be determined, the TrEMBL accession number was identified using the same process. If no TrEMBL accession number could be identified, then the protein sequence from the NCBI database was used directly in the analysis.
In silico trypsin digestion
Peptide fragments generated by trypsin digestion were predicted using the "PeptideMass" program [19] , accessed through the ExPASy proteomics server (http://www.expasy.org/tools/peptide-mass.html). The SwissProt protein identifier or the TrEMBL accession number was used to identify the protein or the amino acid sequence transferred from the NCBI record. Trypsin was selected as the enzyme, and the option to include "all known post-translational modifications" was selected. The other parameters were as follows: Cysteines were treated with "nothing"; peptide masses were isotopic and uncharged; zero missed cleavages were allowed; and peptides of a mass greater than 500 Da were displayed. These parameters will predict peptides that are readily characterizable using the currently available MS equipment.
N-linked glycosylation sites
For proteins with a SwissProt or TrEMBL identifier, the selection of all known post-translational modifications in the PeptideMass program was used to identify the peptide fragments that contained N-linked glycosylation sites. For the other proteins or where no glycosylation sites were indicated in the SwissProt annotation, potential N-linked glycosylation sites were identified using the "NetNGlyc Server" (http://www.cbs.dtu.dk/services/NetNGlyc/), with the output selected to "Predict only on Asn-Xaa-Ser/Thr sequons." O-linked glycosylation sites were not examined, as a consensus motif has not been identified [20] , making the prediction of which peptides carry O-linked glycosylation too complicated for a rapid analysis.
MASCOT searching
For each protein, the peptides that contained a single cysteine residue were identified. To determine whether a peptide could identify the original protein, the peptide mass and part or all of the sequence were analyzed using the MASCOT sequence query form [21] on the Matrix Science site (http://www. matrix-science.com). For peptide fragments less than six residues, the entire sequence was submitted; for longer fragments, between five and seven residues were submitted. For example, the sequence tag "1436 seq(y [il] [dn]atg)" (where "[il]" and " [dn] " indicate that either amino acid could be present at that position) was submitted as the N -Ͼ C sequence (the default "b-ion" setting) to search with the CD98-derived glycosylated peptide SLVTQLϽNϾATGNR (amino acids 316 -329 of CD98, where the ϽNϾ residue is predicted to be glycosylated). The following parameters were used in the form: NCBInr database; Homo sapiens taxonomy; trypsin as the enzyme; no missed cleavages allowed; no modifications selected; peptide tolerance of Ϯ2 Da; MS/MS tolerance of Ϯ0.8 Da; the peptide charge as "molecular weight" (no peptide charge); and the masses as monoisotopic. The score of the top match was recorded, and if the top match were not the source protein, then the position of the protein in the list was recorded. If the top match were not the correct protein, but the score for the correct protein was close to the score of the top match, then the sequences were compared by a pair-wise BLAST alignment to determine whether they were independent submissions to the database of a single sequence or whether the entries were distinct sequences. If they were, then the peptide was included as having identified the correct protein.
Data compilation
The following data were collected for each protein analyzed: the predicted polypeptide mass; the total number of peptides with a mass between 500 and 2000 Da; the number of peptides in this size range with a single cysteine; and the number of peptides in this size range with an N-linked glycosylation site.
Protein identification using cysteine-containing peptides
Protein identifications were rejected if the following set of criteria were not met for two or more peptides predicted from trypsin digestion: The peptides were of a mass between 500 and 2000 Da; a single cysteine residue was present in each peptide; there were no predicted N-glycosylation sites; and the peptides identified the original protein using the (MASCOT) search engine.
Protein identification using glycosylated peptides
Protein identifications were rejected if the following set of criteria were not met for two or more peptides predicted from trypsin digestion: The peptides were of a mass between 500 and 2000 Da; the peptide included a predicted N-linked glycosylation site; and the peptides identified the original protein using the (MASCOT) search engine.
RESULTS
The protein sequences of 261 CD molecules were analyzed. The 59 remaining CD molecule designations, which were not 
No peptides in the size range that contained a single cysteine. n ϭ 20 CD24, CD43, CD47, CD52, CD74, CD111, CD138, CD162, CD195, CD224, CD225, CD227, CD235a, CD235b, CD236, CD240CE, CD240D, CD241, CD244, CD247 Only one peptide in the size range that contained a single cysteine. n ϭ 30
CD3e, CD3g, CD8a, CD8b, CD9, CD20, CD33*, CD36, CD53, CD58ˆ, CD66b, CD66c*, CD66d, CD68, CD80*, CD84, CD85a, CD98, CD99, CD107a, CD109, CD144, CD153, CD155*, CD164, CD201, CD212, CD231, CD233, CD234 More than one cysteine-containing peptide in the size range, but only one peptide had a single cysteine residue and/or no N-linked glycosylation site. n ϭ 16 CD22, CD42c, CD48, CD66a, CD79a, CD82, CD85i, CD102, CD107b, CD114, CD116, CD122, CD131, CD134, CD137, CD147
The MASCOT search did not return the correct sequence using any cysteine-containing peptides in the size range. n ϭ 22
CD16a, CD16b, CD32a, CD32b, CD32c, CD128a, CD128b, CD140a, CD140b, CD158a, CD158b1, CD158b2, CD158d, CD158e1, CD158e2, CD158g, CD158h, CD158i, CD158j, CD158k, CD179a, CD179b
* The single peptide contained a predicted glycosylation site.ˆThe candidate peptide contained more than one cysteine residue. In either case, the peptide would have failed the selection criteria. CD8b, CD9, CD16a, CD16b, CD24, CD25, CD32a, CD32b, CD32c, CD42a, CD42c, CD66d, CD74, CD84, CD85a, CD85i, CD85j, CD88, CD104, CD112, CD120b, CD128a, CD128b, CD129, CD138, CD151, CD152, CD154, CD158d, CD162, CD164, CD167a, CD172a, CD177, CD183, CD184, CD195, CDw197, CD200, CD201, CD223, CD225, CD227, CD231, CD234, CD235b, CD240CE, CD240D, CD241, CD242, CD243, CD247 Only one peptide in the size range had a glycosylation site. n ϭ 66
CD1a, CD1c, CD1d, CD1e, CD2, CD3d, CD4, CD5, CD7, CD14, CD19, CD22, CD23, CD27, CD34, CD37, CD40, CD41, CD42b, CD46, CD48, CD52, CD53, CD55, CD58, CD68, CD69, CD70, CD72, CD79a, CD79b, CD82, CD85d, CD85e, CD85h, CD86, CDw92, CDw93, CD94, CD95, CD105, CD106, CD110, CD114, CD120a, CD123, CD126, CD132, CD134, CD140a, CD141, CD157, CD158e1, CD158e2, CD158j, CD158k, CD160, CD161, CD174, CD178, CD209, CD212, CD230, CD233, CD236, CD239 The MASCOT search did not return the correct sequence using any glycosylated peptides in the size range. n ϭ 4 CD47, CD158b1, CD158b2, CD158h analyzed, include reserved designations (e.g., CD113, CD185), carbohydrate molecules (e.g., CD15, CD77), deleted or reassigned designations (e.g., CD67, CD78), or CD molecules that have not been cloned or for which no definitive sequence could be identified (e.g., CD139, CD165). SwissProt identifiers could be determined for 239 CD molecules, and TrEMBL identifiers were determined for the other 22 molecules. There was a linear relationship between the predicted size of the protein and the number of peptides between 500 and 2000 Da, which would be generated by trypsin digestion (R 2 ϭ0.87; Fig. 1A) . In contrast, the relationships between the total number of peptides in the size range and the number of peptides with a single cysteine residue (R 2 ϭ0.63; Fig. 1B ) or the number of peptides with N-linked glycosylation (R 2 ϭ0.55; Fig. 1C) were not strong.
The MASCOT search for the example CD98-derived sequence tag 1436 seq(y [il] [dn]atg) returned four database entries with an identical score of 72 (for this search, scores above 63 were significant). The four database entries that were returned (gi_21361344, gi_178685, gi_177207, and gi_177216) all correspond to the target sequence (CD98), but the entries have been submitted by different individuals or represent a curated sequence (gi_21361344).
A protein identification approach using two peptides containing a single cysteine residue was not able to identify 88 of the CD molecules (33.7% of the sequences analyzed), as listed in Table 1 . An identification approach using glycosylated peptides was not able to identify 130 CD molecules (49.8% of the sequences analyzed), as listed in Table 2 . The reasons why particular CD molecules could not be identified using either method are summarized in Figure 2 . In most cases, the sequences did not generate two or more suitable cysteinecontaining or glycosylated peptides.
In the analysis of glycosylated peptides, the database search failed for peptides derived from four sequences. Three of these were closely related sequences (CD158b1, CD158b2, CD158h), which produced identical peptide fragments. In the case of the fourth protein (CD47), one of the predicted glycosylated peptides was located immediately following the signal sequence. The fragment used in the MASCOT search did not include the signal sequence; however, the database entry for the protein included the signal sequence, leading to a larger fragment being expected (Fig. 3) .
There were 103 CD molecules (39.4%), which could be identified by both protein identification approaches used (Table 3), and there were 60 CD molecules (23.0%), which could not be detected by either method ( Table 4 ). The numbers in each category are summarized in Table 5 .
To illustrate two difficulties presented by the analysis, details of the analysis for two CD molecules are presented in Figure 4 and Table 6 . The CD32 family of Fc receptors (FcRs) is distinct, functionally and by their expression patterns [22] . In silico prediction of the peptides generated by trypsin digestion indicates that the three members of the family, CD32a, CD32b and CD32c, would yield several common peptides, including the only peptide of between 500 and 2000 Da that contains a cysteine residue (Fig. 4) . A database search using these shared peptides cannot discriminate between the different family members.
A different situation, seen with peptides from the CD169 protein, can arise from the redundancy of the databases used for searching. The in silico trypsin digestion predicts Tables 1 and 2 . "No Glycosylation" indicates the number of CD molecules that were not glycosylated. "No Peptides" indicates that no peptides in the size range contained a cysteine residue peptide or a glycosylation site. "Single peptide" indicates that only one in the size range contained a cysteine residue. "One suitable peptide" indicates that only one peptide with a cysteine residue peptide or a glycosylation site was present. "Search failed" indicates that the MASCOT search did not return the correct sequence. the generation of 60 peptides of between 500 and 2000 Da, of which nine contain a single cysteine residue and another three have a predicted N-linked glycosylation site. The database search performed with several of these peptides returned matches to several proteins as well as the correct match ( Table 6 ). The source of the matched sequences are as follows: gi_28273128, gi_10440432, and gi_10440438 were isolated from human spleen cDNA libraries prepared in the same laboratory; gi_11493364 was identified by its homology with CD169 during the genome sequencing project; gi_13489095 is the NBCI reference sequence for CD169; and gi_12656130 is the original CD169 sequence deposited in the NCBI database, which was used to generate the reference sequence. BLAST analyses of the first four sequences listed return each of the others and the CD169 reference sequences, suggesting that these are fragments of the CD169 protein (data not shown).
DISCUSSION
Plasma membrane proteins expressed by leukocytes are involved in a range of functions critical to the interaction of cells with their environment. Using mAb and more recently, gene analysis techniques, the seven HLDA workshops have characterized the expression of 320 cell-surface proteins expressed on the surface of leukocytes. It is clear from a number of sources that there are many more proteins expressed in leukocyte plasma membranes that have not been identified using these approaches. MS-based protein identification, using affinity chromatography to isolate proteins with exposed extracellular domains, provides a means to identify and characterize those cell-surface proteins that have not been identified through traditional means. We have examined two approaches used to affinity-isolate plasma membrane proteins to determine how effective they are likely to be in the identification of uncharacterized proteins.
Our results demonstrate that the isolation of peptides through N-linked glycosylation or thiol bonds can be used in conjunction with MS analysis to identify most (77%) of the known CD molecules (201 of 261 analyzed). Given that large size of the dataset and that it is representative of the diversity of plasma membrane proteins, this would suggest that these same approaches would be valuable for the detection and characterization of other cell-surface proteins that have not yet been identified. It is also evident that no single approach can be used to identify all the proteins in a particular sample and that other methods of isolating proteins and/or peptides will be needed to ensure that a complete coverage of the cell-surface proteins is obtained.
The analysis described here required that two peptides identify the target protein in the database source. The identification of proteins using peptide mass tags is a probabilitybased process [21, 23] , which can be affected by a variety of CD49c,  CD73,  CD124,  CD169,  CD221,  CD11d,  CD49d,  CD83,  CDw125,  CD170,  CD222,  CD13,  CD49e,  CD87,  CD127,  CD171,  CD226,  CD18,  CD49f,  CD89,  CD130,  CD180,  CD228,  CD21,  CD50,  CD90,  CD133,  CDw197,  CD229,  CD26,  CD51,  CD91,  CD135,  CD202b,  CD232,  CD28,  CD54,  CDw92,  CD136,  CD203c,  CD238,  CD29,  CD56,  CD96,  CD142,  CD204,  CD246  CD30,  CD59,  CD97,  CD143,  CD205,  CD31,  CD61,  CD100,  CD146,  CD206 factors including the quality of the MS spectra, the mass accuracy of the peptide mass determinations, and the quality of the sequence database. Although it is possible to identify a protein using a single peptide sequence tag [23] , mixtures of peptides can often result in poor quality MS-MS and the failure to identify a correct parent protein [18, 24] . Thus, the need for two peptide sequence tags to contribute to the identification of the parent protein increases the confidence of the match [16] . In the approaches examined here, further confidence in the assignments can be gained by the requirement that the peptide sequence contains a cysteine residue or a motif for N-linked glycosylation. In the present study, an "in silico" analysis of database searches using peptide sequence tags means that factors such as MS spectra quality and mass accuracy could be ignored, and this allowed us to address whether a "perfect" peptide sequence tag is capable of identifying the parent protein when it is known to be in the database.
There are a number of factors that affected the identification of CD molecules using the approaches described and that would also impact on the use of these approaches for the identification of new cell-surface molecules. For example, the CD20 molecule, which is commonly used to identify B lymphocytes, has no N-linked glycosylation sites and generated only one peptide with a cysteine residue in the specified size range. A similar situation was observed with the CD8 ␣-and ␤-chains. The detection of these proteins would require the use of alternative methods. In other cases, such as the low-affinity immunoglobulin G FcR-2 proteins (CD32a, CD32b, and CD32c), closely related but functionally distinct proteins could not be distinguished, as they generated a number of identical peptides. "Identified" indicates that there were two or more peptides that met the selection criteria used here. "Not identified" indicates that this was not the case for the reasons indicated in Table 1 The underlined portion of the peptide sequence indicates the tag used in the search. The gi numbers are the NCBI accession numbers of the protein sequences of the matches. The score returned by the MASCOT algorithm (shown in brackets) is "Ϫ10*Log(P), where P is the probability that the observed match is a random event." Sequences gi_13489095 and gi_12656130 (indicated by a "ϩ" next to the score) are correct CD169 entries; the other entries (indicated by a "Ϫ") are nonidentical but related sequences.
